Psychoeducational intervention changes patient attitudes on clinical trials participation

June 13, 2012 in Cancer

Seeking ways to change cancer patients' perceptions and negative attitudes towards clinical trials participation, researchers at Moffitt Cancer Center conducted a study offering two different kinds of intervention to two groups of adults with cancer who had not previously been asked to participate in clinical trials. They found a multimedia psychoeducational intervention to be more effective in changing patients' perceptions and negative attitudes toward clinical trials than standard educational literature.

The study was published in a recent issue of the Journal of Clinical Oncology.

"Clinical trials are critical to the development of more effective cancer treatments," said study lead author Paul B. Jacobsen, Ph.D., senior member at Moffitt and associate center director for Population Science. "However, clinical trials are hampered by low rates of patient participation."

According to Jacobsen and colleagues, the low rates of patient participation point to the need to develop interventions that will increase the likelihood of patients enrolling in clinical trials. Many interventions used in the past, they noted, focused on improving the consenting process rather than changing about clinical trials.

"Research has consistently revealed that patients have and attitudes about clinical trials," explained Jacobsen. "We hypothesized that the right intervention would have a positive impact in changing perceptions and attitudes towards participation."

For this study, 472 who had not previously been asked to participate in a clinical trial were divided into two groups: one group viewed a new, 18-minute multimedia psychoeducational presentation, and the second group received existing printed about clinical trials.

"Our results demonstrated the benefits of providing patients with a brief, multimedia psychoeducational program focused on changing attitudes towards clinical trials," wrote the researchers. "The group receiving the multimedia psychoeducational intervention developed a more positive attitude and demonstrated an increased willingness to enroll in a clinical trial when compared with the group receiving printed educational material."

"Although the effects were modest, the successful intervention has the potential to reach a large number of patients and, thus, have broad impact," wrote the researchers. "The psychoeducational multimedia presentation requires relatively little time, effort and resources to deliver."

Journal reference: Journal of Clinical Oncology search and more info website

Provided by H. Lee Moffitt Cancer Center & Research Institute search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created 11 hours ago | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created 12 hours ago | popularity not rated yet | comments 0 | with audio podcast

Physical & emotional impairments common, often untreated in people with cancer

A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...

Cancer created 16 hours ago | popularity not rated yet | comments 0

Calif. doc with 'cancer cure' gets 14 years prison (Update)

(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.

Cancer created 17 hours ago | popularity not rated yet | comments 0

New protein-targeting drug shows promise in early trial for patients with high-risk CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...

Cancer created 18 hours ago | popularity not rated yet | comments 0 | with audio podcast


AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests

Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...

Temporal processing in the olfactory system

The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...

Melon focus headband turns to Kickstarter for rollout plans

(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...